Ordinate = TCID 50, titer in logs abscissa = concentration of iota-carrageenan in µg/ml MOCK = untreated control cells Fig.3A = cells infected with HRV-1A Fig.3B=cells infected with HRV-2 Fig.3C=cells infected with HRV-8 Fig.3D=cells infected with HRV-16 Fig.3E=cells infected with HRV-39 Fig.3F=cells infected with HRV-83. Fig.3 shows the efficacy of iota-carrageenan on inhibition of rhinovirus replication on infected human nasal epithelial cells determined by TCID 50 assays. The peak titers were observed at day 3 for HRV-2 ( Fig2A) and at day 4 for HRV-14 ( Fig2B). Further processing was identical to T: cells were infected at a multiplicity of infection of 0.01. Ordinate=TCID 50 titer abscissa = concentration of iota-carrageenan in µg/ml U = untreated cells T (treatment) = cells were infected for one hour and the indicated concentration of iota-carrageenan was added one hour after treatment P (prophylaxis) = the virus suspension was preincubated with the indicated concentration of iota-carrageenan for on hour before infection. Fig.2 shows the determination of peak titers of supernatants from infected Hela cells by TCID 50 assays. Ordinate = OD measured at 492nm abscissa = different test samples 1 = uninfected cells 2 = untreated, infected cells 3 = infected cells treated with iota-carrageenan 4=infected cells treated with kappa-carrageenan 5= infected cells treated with lambda-carrageenan Fig.1A=cells infected with HRV-2 Fig.1B=cells infected with HRV-14.
Original Assignee Marinomed Biotechnologie GmbH Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
( en Inventor Andreas Grassauer Eva Prieschl-Grassauer Christiane Meier Alexander Pretsch Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Application number EP07856354A Other languages German ( de)
IOTA CARRAGEENAN NASAL SPRAY AMAZON PDF
Google Patents Use of carrageenan for treating rhinovirus infectionsĭownload PDF Info Publication number EP2101792B1 EP2101792B1 EP07856354A EP07856354A EP2101792B1 EP 2101792 B1 EP2101792 B1 EP 2101792B1 EP 07856354 A EP07856354 A EP 07856354A EP 07856354 A EP07856354 A EP 07856354A EP 2101792 B1 EP2101792 B1 EP 2101792B1 Authority EP European Patent Office Prior art keywords carrageenan composition iota use according hygiene Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents EP2101792B1 - Use of carrageenan for treating rhinovirus infections EP2101792B1 - Use of carrageenan for treating rhinovirus infections
0 kommentar(er)
